Finally, PTX3 has also been described to have systemic effects as an immunotherapeutic in multiple rodent models of infection, and its therapeutic activity in vivo is thought to be based on its ability to promote a balanced Th1-mediated inflammatory response and modulate the recruitment, phagocytosis, and antimicrobial activity of inflammatory cells [21–26]. The gene discussed is PTX3; the disease is infection.